What is Rallybio Corp (RLYB) stock price today?

Rallybio Corp (RLYB) currently trades at $8.98 per share. The stock has a market capitalization of $46.55M and a P/E ratio of —x.

Is RLYB stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Rallybio Corp has a Smart Value Score of 37/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is 0.91.

What is Rallybio Corp's revenue and earnings?

Rallybio Corp has trailing twelve-month (TTM) revenue of $858000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-1.59.

Is Rallybio Corp financially healthy?

Rallybio Corp's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of 0.91 places it in the distress.

RLYB

Rallybio Corp

NASDAQ: RLYB · HEALTHCARE · BIOTECHNOLOGY

$8.98

+1.13% today

Updated 2026-04-30

Market cap

$46.55M

P/E ratio

—

P/S ratio

54.25x

EPS (TTM)

$-1.59

Dividend yield

—

52W range

$2 – $11

Volume

0.2M

Market cap

$46.55M

P/E ratio

—

P/S ratio

54.25x

EPS (TTM)

$-1.59

Dividend yield

—

52W range

$2 – $11

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

6.3

Growth

7.0

Quality

B+

2.5

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

0.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$8.00

-10.91%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy0 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 484.20% QoQ

+ Debt/equity 0.00x — low leverage

Risks

- Altman Z 0.91 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-4.68M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$636000.00	$858000.00	$858000.00
Net income	$-66.65M	$-74.56M	$-57.77M	$-8.98M	$-5.85M
EPS	—	—	—	—	$-1.59
Free cash flow	$-57.34M	$-60.28M	$-49.28M	$-29.81M	$-4.68M
Profit margin	—	—	-9,084.12%	-1,046.39%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RLYB	$46.55M	37	6.3	2.5	5.0	7.0	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Rallybio Corp trades at $8.98. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.91, it sits in the distress. TTM revenue stands at $858000.00.

Frequently asked questions

What is Rallybio Corp's stock price?

Rallybio Corp (RLYB) trades at $8.98.

Is Rallybio Corp overvalued?

Smart Value Score 37/100 (Grade D, Sell).

What is the price target of Rallybio Corp (RLYB)?

The analyst target price is $8.00, representing -10.9% downside from the current price of $8.98.

What is Rallybio Corp's revenue?

TTM revenue is $858000.00.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

0.91 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.rallybio.com

Quick metrics

P/S ratio54.25x

ROE-15.00%

Beta-1.20

50D MA$8.39

200D MA$5.75

Shares out0.01B

Float0.00B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RLYB vs LLY →RLYB vs JNJ →RLYB vs ABBV →Stock screener →